mRNA and CRISPR Patent Wars: What Every Life Sciences Business Executive and Counsel Need to Know
Supervisory Patent Examiner, Quality Assurance Specialist
VP, Head of IP and Legal
Arbor Biotechnologies, Inc.
Loeb & Loeb LLP
VP & Head of IP
Kramer Levin Naftalis & Frankel LLP
Patent fights rarely demand the attention of the industry the way one battle has, and one battle may.
After numerous skirmishes in the district courts, the latest round of the CRISPR battle took place before the USPTO’s PTAB which ruled each party completed on the gene editing tech doesn’t overlap and can be separately patented. Additionally, the two leading COVID-19 vaccines on the market, introduced by Moderna Inc. and BioNTech SE are currently the subject of major patent litigations relating to how those therapies are delivered.
The implications of these cases are not only for the lawyers in the room – as this panel will provide an overview of these battles and detail the critical business implications which they present. Topics of discussion will include:
- Detailing the status of these patent wars
- Understanding how they will impact collaboration and tech transfers
- Determining if these on-going cases will interfere with future R&D and commercialization
- Considering different business models and the emerging landscape of gene editing